Gastrointestinal/GI Tract Cancer | Stomach, Colon Cancer News

Gastrointestinal Cancer

Gastrointestinal Cancer News & Features

Ayvakit Approval for GI Stromal Tumor With PDGFRA Mutation

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Next post in Gastrointestinal Cancer